Profitability Ratios
| Ratio |
Value |
| GP Margin |
97.3% |
| EBIT Margin |
-281.0% |
| EBITDA Margin |
-278.4% |
| Operating Margin |
-343.6% |
| Pretax Margin |
-281.0% |
| Cont. Ops Margin |
-282.8% |
| Net Margin |
-282.8% |
| Bottom Line Margin |
-282.8% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
12.71 |
| Quick Ratio |
12.71 |
| Solvency Ratio |
-2.336 |
| Cash Ratio |
2.83 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
|
| PEG Ratio |
0.29 |
| Forward PEG |
0.29 |
| Price/Book |
9.03 |
| Price/Sales |
120.66 |
| Price/FCF |
99.01 |
| Price/Op Cash Flow |
96.28 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.0154 |
| Debt/Equity |
0.0168 |
| Debt/Capital |
0.0165 |
| Long-Term Debt/Capital |
0.0000 |
| Financial Leverage |
1.09 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
0.09 |
| Operating Cash Flow Ratio |
1.269 |
| Operating Cash Flow/Sales |
125.3% |
| Free Cash Flow/Operating Cash Flow |
97.2% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
-56.47 |
| Interest Coverage |
0.0000 |
| Short-Term Operating Cash Flow Coverage |
25.26 |
| Operating Cash Flow Coverage |
5.59 |
| Capital Expenditure Coverage |
36.27 |
| Dividend + Capital Expenditure Coverage |
36.27 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
0.0000% |
| Dividend Yield |
0.0000% |
| Dividend Yield % |
0.0000% |
| Dividend Per Share |
0.0000 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
0.72 |
| EPS |
-2.047 |
| Debt/Share |
0.1624 |
| Cash/Share |
8.92 |
| Book Value/Share |
9.67 |
| Tangible BV/Share |
9.67 |
| Equity/Share |
9.67 |
| Operating Cash Flow/Share |
0.907 |
| Capital Expenditure/Share |
0.025 |
| FCF/Share |
0.882 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
1.006 |
| Earnings Before Tax/EBIT |
0.818 |
| Price/Fair Value |
9.03 |
| Debt/Market Cap |
0.0004 |
| Effective Tax Rate |
-0.6% |
| Enterprise Value Multiple |
-42.43 |
PTGX - Protagonist Therapeutics, Inc.